GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Net Margin %

Apogee Therapeutics (Apogee Therapeutics) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Apogee Therapeutics's Net Income for the three months ended in Mar. 2024 was $-32.09 Mil. Apogee Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Apogee Therapeutics's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Apogee Therapeutics's Net Margin % or its related term are showing as below:


APGE's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.37
* Ranked among companies with meaningful Net Margin % only.

Apogee Therapeutics Net Margin % Historical Data

The historical data trend for Apogee Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Net Margin % Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23
Net Margin %
- -

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Apogee Therapeutics's Net Margin %

For the Biotechnology subindustry, Apogee Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apogee Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's Net Margin % falls into.



Apogee Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Apogee Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-83.985/0
= %

Apogee Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-32.094/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apogee Therapeutics  (NAS:APGE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Apogee Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apogee Therapeutics (Apogee Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Executives
Mark C. Mckenna director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson officer: Chief Financial Officer C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr director NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson director, officer: Chief Executive Officer 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener director 3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski officer: Chief Medical Officer 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453

Apogee Therapeutics (Apogee Therapeutics) Headlines